AR106687A1 - PROCESO PARA PREPARAR UNA FORMULACIÓN EN POLVO SECO QUE COMPRENDE UN ANTICOLINÉRGICO, UN CORTICOSTEROIDE Y UN b-ADRENÉRGICO - Google Patents

PROCESO PARA PREPARAR UNA FORMULACIÓN EN POLVO SECO QUE COMPRENDE UN ANTICOLINÉRGICO, UN CORTICOSTEROIDE Y UN b-ADRENÉRGICO

Info

Publication number
AR106687A1
AR106687A1 ARP160103472A ARP160103472A AR106687A1 AR 106687 A1 AR106687 A1 AR 106687A1 AR P160103472 A ARP160103472 A AR P160103472A AR P160103472 A ARP160103472 A AR P160103472A AR 106687 A1 AR106687 A1 AR 106687A1
Authority
AR
Argentina
Prior art keywords
corticosteroid
dry powder
formulation
adrenergic
polynergic
Prior art date
Application number
ARP160103472A
Other languages
English (en)
Spanish (es)
Inventor
Ortenzi Leonardo
Cafiero Claudio
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54548063&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR106687(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of AR106687A1 publication Critical patent/AR106687A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP160103472A 2015-11-16 2016-11-14 PROCESO PARA PREPARAR UNA FORMULACIÓN EN POLVO SECO QUE COMPRENDE UN ANTICOLINÉRGICO, UN CORTICOSTEROIDE Y UN b-ADRENÉRGICO AR106687A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15194661 2015-11-16

Publications (1)

Publication Number Publication Date
AR106687A1 true AR106687A1 (es) 2018-02-07

Family

ID=54548063

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103472A AR106687A1 (es) 2015-11-16 2016-11-14 PROCESO PARA PREPARAR UNA FORMULACIÓN EN POLVO SECO QUE COMPRENDE UN ANTICOLINÉRGICO, UN CORTICOSTEROIDE Y UN b-ADRENÉRGICO

Country Status (31)

Country Link
US (3) US10086003B2 (enExample)
EP (2) EP3377109B1 (enExample)
JP (1) JP6942126B2 (enExample)
KR (1) KR20180082442A (enExample)
CN (1) CN108348614B (enExample)
AR (1) AR106687A1 (enExample)
AU (1) AU2016357988B2 (enExample)
CA (1) CA3005291C (enExample)
CL (1) CL2018001297A1 (enExample)
CO (1) CO2018005139A2 (enExample)
DK (2) DK3377109T3 (enExample)
EA (1) EA037346B1 (enExample)
ES (2) ES2789365T3 (enExample)
GE (2) GEP20207178B (enExample)
HR (2) HRP20211599T1 (enExample)
HU (2) HUE050343T2 (enExample)
IL (1) IL259327B (enExample)
MA (1) MA52437A (enExample)
MX (1) MX377113B (enExample)
MY (1) MY198321A (enExample)
PE (1) PE20181377A1 (enExample)
PH (1) PH12018501023A1 (enExample)
PL (2) PL3689379T3 (enExample)
PT (2) PT3689379T (enExample)
SA (1) SA518391574B1 (enExample)
SG (2) SG10201912090UA (enExample)
SI (2) SI3689379T1 (enExample)
TW (1) TWI729025B (enExample)
UA (1) UA125173C2 (enExample)
WO (1) WO2017085007A1 (enExample)
ZA (1) ZA201803167B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018206619A1 (en) * 2017-05-11 2018-11-15 Chiesi Farmaceutici S.P.A. A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
WO2018206618A1 (en) * 2017-05-11 2018-11-15 Chiesi Farmaceutici S.P.A. A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
WO2019060595A1 (en) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
US11304901B2 (en) * 2019-08-28 2022-04-19 Anovent Pharmaceutical (U.S.), Llc Liposome formulation of fluticasone furoate and method of preparation
WO2021143785A1 (zh) * 2020-01-15 2021-07-22 四川海思科制药有限公司 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法
CN111467498A (zh) * 2020-05-14 2020-07-31 王兆霖 药物组合物制剂
CN117064869B (zh) * 2023-09-27 2026-05-12 山东京卫制药有限公司 一种胶囊型吸入粉雾剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
PT1386630E (pt) 2002-07-31 2006-09-29 Chiesi Farma Spa Inalador em po
EP1646370A1 (en) * 2003-07-11 2006-04-19 Glaxo Group Limited Pharmaceutical formulations
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
RU2580312C2 (ru) 2010-04-21 2016-04-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способ получения частиц с пониженным электростатическим зарядом
US9393202B2 (en) 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
LT3019153T (lt) * 2013-07-11 2018-11-26 Chiesi Farmaceutici S.P.A. Sausų miltelių kompozicija, apimanti anticholinerginį agentą, kortikosteroidą ir beta-adrenerginį agentą, skirta įvedimui inhaliacijos pagalba

Also Published As

Publication number Publication date
ES2789365T3 (es) 2020-10-26
GEAP201614782A (enExample) 2020-04-27
TW201722403A (zh) 2017-07-01
CA3005291A1 (en) 2017-05-26
UA125173C2 (uk) 2022-01-26
SI3377109T1 (sl) 2020-07-31
WO2017085007A1 (en) 2017-05-26
AU2016357988B2 (en) 2021-12-16
BR112018009811A8 (pt) 2019-02-26
US10959944B2 (en) 2021-03-30
MX2018005979A (es) 2018-08-29
SI3689379T1 (sl) 2021-11-30
TWI729025B (zh) 2021-06-01
PH12018501023B1 (en) 2018-12-17
EP3377109A1 (en) 2018-09-26
JP6942126B2 (ja) 2021-09-29
HUE056402T2 (hu) 2022-02-28
CA3005291C (en) 2024-01-16
PT3689379T (pt) 2021-09-24
DK3689379T3 (da) 2021-09-06
KR20180082442A (ko) 2018-07-18
MA52437A (fr) 2021-05-05
CN108348614A (zh) 2018-07-31
PL3377109T3 (pl) 2020-09-21
GEP20207178B (en) 2020-11-10
US10786451B2 (en) 2020-09-29
PT3377109T (pt) 2020-05-13
AU2016357988A1 (en) 2018-05-31
ES2890409T3 (es) 2022-01-19
HUE050343T2 (hu) 2020-11-30
US10086003B2 (en) 2018-10-02
IL259327B (en) 2020-11-30
HRP20211599T1 (hr) 2022-01-07
PH12018501023A1 (en) 2018-12-17
EP3689379A1 (en) 2020-08-05
HK1256859A1 (zh) 2019-10-04
EP3377109B1 (en) 2020-03-04
EA037346B1 (ru) 2021-03-16
JP2018537453A (ja) 2018-12-20
EA201890967A1 (ru) 2018-12-28
MX377113B (es) 2025-03-07
SA518391574B1 (ar) 2021-06-13
HRP20200571T1 (hr) 2020-07-10
US20200360278A1 (en) 2020-11-19
BR112018009811A2 (pt) 2018-11-13
EP3689379B1 (en) 2021-08-11
PE20181377A1 (es) 2018-09-05
CL2018001297A1 (es) 2018-08-10
NZ742473A (en) 2024-11-29
PL3689379T3 (pl) 2021-12-13
CO2018005139A2 (es) 2018-08-10
IL259327A (en) 2018-07-31
US20190021994A1 (en) 2019-01-24
CN108348614B (zh) 2021-09-21
MY198321A (en) 2023-08-24
GEAP202014782A (en) 2020-04-27
DK3377109T3 (da) 2020-04-20
SG10201912090UA (en) 2020-02-27
US20170136034A1 (en) 2017-05-18
ZA201803167B (en) 2019-07-31
SG11201804048WA (en) 2018-06-28

Similar Documents

Publication Publication Date Title
MX2024013963A (es) Un antagonista de il-4r util para el tratamiento o la prevencion del asma
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
MX2017001637A (es) 2-(morfolin-4-il)-1,7-naftiridinas.
MX377377B (es) Composiciones tópicas para el alivio del dolor, manufactura y uso.
AR106688A1 (es) PROCESO PARA PREPARAR UNA FORMULACIÓN EN POLVO SECO QUE COMPRENDE UN ANTICOLINÉRGICO, UN CORTICOSTEROIDE Y UN b-ADRENÉRGICO
CR20170076A (es) Derivados de pirimidima sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
CL2015000744A1 (es) Combinación de regorafenib y ácido acetilsalicílico para el tratamiento del cáncer.
MX2018005979A (es) Proceso para preparar una formulacion en polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico.
DOP2017000107A (es) Diamino-quinoleina 2,4 sustituida como nuevos agentes anticancerigenos
BR112018072113A2 (pt) excipiente à base de proteínas para ingredientes farmacêuticos ativos
CO2017008031A2 (es) Compuestos con actividad antagonista de los receptores muscarínicos y actividad agonista del receptor beta2 adrenérgico
CL2016002848A1 (es) Combinaciones de bromuro de tiotropio, formoterol y budesonida para el tratamiento de la copd
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
UY36329A (es) NUEVOS DERIVADOS BICÍCLICOS QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENÉRGICOS ß2 Y COMO ANTAGONISTAS MUSCARÍNICOS M3
AR100784A1 (es) Micropartículas multicomponentes para usar en una formulación inhalable, proceso para preparar, formulación farmacéutica, inhalador
MX2018014184A (es) Triple combinacion de antagonistas del receptor de 5-ht6 puro, inhibidores de acetilcolinesterasa y antagonista del receptor de nmda.
MX376160B (es) Compuestos que tienen actividad antagonista del receptor muscarínico y actividad agonista del receptor beta2 adrenérgico.
CL2016001429A1 (es) Formas polimórficas de un compuesto similar a un esteroide y metodos para la preparación y su uso
PE20170919A1 (es) Formulacion inhalable
CN302550275S (zh) 割草机割草刀测试检具
TR201716155A1 (tr) Bir beta-2 agonisti ile birlikte bir kortikosteroid içeren farmasötik formülasyon.
CN302518780S (zh) 灌装机

Legal Events

Date Code Title Description
FC Refusal